Truist Financial Corp Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Truist Financial Corp cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,221 shares of the biopharmaceutical company’s stock after selling 1,630 shares during the quarter. Truist Financial Corp’s holdings in Regeneron Pharmaceuticals were worth $42,274,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Brown Lisle Cummings Inc. grew its stake in Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 10 shares during the period. Sachetta LLC grew its position in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Team Hewins LLC increased its stake in Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the last quarter. Angeles Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 3.5% during the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares during the period. Finally, Western Financial Corp CA boosted its stake in Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after buying an additional 12 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ REGN opened at $1,040.27 on Thursday. The company’s fifty day simple moving average is $1,127.95 and its 200-day simple moving average is $1,036.76. The stock has a market cap of $114.68 billion, a P/E ratio of 30.73, a PEG ratio of 3.56 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $8.79 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on REGN shares. Wells Fargo & Company reaffirmed an “overweight” rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 23rd. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating on the stock in a report on Tuesday, September 24th. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 25th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,118.62.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,033 shares of company stock worth $9,399,345. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.